Sarah Evans
Acute Care · du Bois, PANPI 1922358555
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 323 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 9.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,874, 3.3 times the $565 reported in 2021. Among acute care clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 323 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$598
- Amgen$574
- Bayer$546
- OPKO Pharmaceuticals, LLC$451
- Novartis$431
- Travere Therapeutics, Inc.$307
- plus $3K from 30 others
What the payments were for
- Consulting fees$1502%
- Food & beverage$5,95896%
- Education$942%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 34 | $598 |
| Amgen(2 entities) | 33 | $574 |
| Bayer | 42 | $546 |
| OPKO Pharmaceuticals, LLC | 27 | $451 |
| Novartis | 22 | $431 |
| Travere Therapeutics, Inc. | 8 | $307 |
| Akebia Therapeutics Inc | 11 | $253 |
| Johnson & Johnson | 16 | $246 |
| Kyowa Kirin, Inc. | 6 | $237 |
| Ardelyx, Inc. | 7 | $226 |
| Aurinia Pharma U.S., Inc. | 12 | $222 |
| Otsuka America Pharmaceutical, Inc. | 11 | $210 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $197 |
| Fresenius USA Marketing, Inc. | 10 | $195 |
| Mallinckrodt Hospital Products Inc. | 9 | $189 |
| Pfizer | 8 | $157 |
| Boehringer Ingelheim | 8 | $134 |
| Calliditas Therapeutics US Inc. | 6 | $134 |
| Vifor Pharma, Inc. | 6 | $127 |
| Daiichi Sankyo Inc. | 6 | $122 |
| Apellis Pharmaceuticals, Inc. | 5 | $97 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $76 |
| Merck | 4 | $68 |
| Inspire Medical Systems, Inc. | 1 | $68 |
| Shield Therapeutics Inc | 3 | $55 |
| GSK | 3 | $46 |
| ANI Pharmaceuticals, Inc. | 2 | $37 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Sanofi | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Medtronic | 1 | $18 |
| Novo Nordisk | 1 | $18 |
| Tersera Therapeutics LLC | 1 | $16 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CRYSVITA$132
- XPHOZAH 30 MG$124
How this compares
$6,202 in reported general payments places this provider in the 95th percentile of 872 acute care providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 74 | $51,392 |
| KerendiaFinerenone | 41 | $32,741 |
| RayaldeeCalcifediol | 19 | $22,916 |
| JardianceEmpagliflozin | 21 | $12,039 |
| OzempicSemaglutide | 12 | $12,024 |
| Valsartan | 42 | $1,349 |
| Allopurinol | 126 | $1,256 |
| Calcitriol | 42 | $1,011 |
| Rosuvastatin Calcium | 61 | $767 |
| Potassium Citrate ErPotassium Citrate | 14 | $661 |
| Atorvastatin Calcium | 59 | $354 |
| Famotidine | 28 | $287 |
| Losartan Potassium | 32 | $190 |
| Lisinopril | 14 | $104 |
| Furosemide | 13 | $82 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $598 | $51,39274 claims |
| BayerKerendia | $546 | $32,74141 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $451 | $22,91619 claims |
| Boehringer IngelheimJardiance | $134 | $12,03921 claims |
| Novo NordiskOzempic | $18 | $12,02412 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $37 | $1,34942 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 872 acute care providers in Pennsylvania.
Other acute care in du Bois
- Crystal Sayersdu Bois$8K
- Kristi MontrellaAltoona$111K
- Kathryn GreenPhiladelphia$92K
- Caroline PratzPhiladelphia$77K
- Donna KinzlerPittsburgh$25K
- Lisa JohnsonPottstown$25K
- Kathryn McParlaneMoon Township$21K
- Rebecca MarcantuonoPhiladelphia$17K
- Stephanie TothPhiladelphia$17K
- Kevin HaganAbington$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.